Wistedt B, Wiles D, Jørgensen A
Psychopharmacology (Berl). 1983;80(2):101-5. doi: 10.1007/BF00427950.
A double-blind withdrawal trial in 41 chronic schizophrenic outpatients was carried out over 6 months. Depot neuroleptics (fluphenazine decanoate or flupenthixol decanoate) were compared with placebo to evaluate neurological side effects during continued therapy and during withdrawal. The drugs were significantly more effective than placebo in preventing relapse and rehospitalization. In the placebo group 62% relapsed compared to 27% in the drug group. A difference was observed in the occurrence of extrapyramidal symptoms (EPS) between the neuroleptics in the study. Akathasia was observed in 9/38 (23.7%) cases, significantly more frequent in the fluphenazine decanoate group. Tardive dyskinesia (TD) was observed in six cases (15.8%); four cases existed at the start of the study and two others were observed after 3-6 weeks of withdrawal. There was no relation between TD symptoms and relapse. There was a significant decrease in the EPS scores during the placebo treatment and also a significant weight decrease.
一项针对41名慢性精神分裂症门诊患者的双盲撤药试验持续了6个月。将长效抗精神病药物（癸酸氟奋乃静或癸酸氟哌噻吨）与安慰剂进行比较，以评估持续治疗期间和撤药期间的神经副作用。这些药物在预防复发和再次住院方面明显比安慰剂更有效。安慰剂组62%复发，而药物组为27%。研究中的抗精神病药物在锥体外系症状（EPS）的发生方面存在差异。静坐不能在9/38（23.7%）的病例中被观察到，在癸酸氟奋乃静组中明显更常见。迟发性运动障碍（TD）在6例（15.8%）中被观察到；4例在研究开始时就存在，另外2例在撤药3 - 6周后被观察到。TD症状与复发之间没有关联。在安慰剂治疗期间EPS评分显著降低，体重也显著下降。
